UGT2B15 genotyping
Jump to navigation
Jump to search
Indications
- evaluation of the pharmacokinetics & pharmacodynamics of lorazepam & oxazepam
Clinical significance
More general terms
Additional terms
References
- ↑ Chung JY, Cho JY, Yu KS Effect of the UGT2B15 genotype on the pharmacokinetics, pharmacodynamics, and drug interactions of intravenous lorazepam in healthy volunteers. Clin Pharmacol Ther. 2005 Jun;77(6):486-94. PMID: https://www.ncbi.nlm.nih.gov/pubmed/15961980
- ↑ He X, Hesse LM, Hazarika S et al Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. Br J Clin Pharmacol. 2009 Nov;68(5):721-30. PMID: https://www.ncbi.nlm.nih.gov/pubmed/19916996 PMCID: PMC2791978 Free PMC article.